About en-newself.com

Who We Are

en-newself.com is an independent editorial and affiliate review website. We are not affiliated with, operated by, or endorsed by NewSelf Limited LLC or the official NewSelf website (newself.com). We are a third-party publisher producing research-based content about compounded GLP-1 medications, telehealth weight loss programs, and the NewSelf platform specifically.

Our team produces in-depth reviews, clinical analysis, pricing guides, competitor comparisons, and regulatory coverage — including content that NewSelf's own marketing does not cover, such as the February 2026 FDA warning letter, the 3-month commitment cancellation terms, the pricing discrepancy across pages, and the mixed independent review scores. If you want the full picture on NewSelf GLP-1 before committing, this is where to find it.

How We Earn Revenue

en-newself.com earns affiliate commissions when visitors click our links and enroll in the NewSelf program. This is disclosed on every page containing affiliate links, per FTC guidelines. Our affiliate relationship does not change the price you pay, the product you receive, or our editorial content. We publish honest pros and cons — including material unfavorable to NewSelf — because our goal is to be genuinely useful to readers making a real healthcare decision, not to maximize affiliate revenue at the expense of accuracy. See our full affiliate disclosure.

Our Editorial Standards

Every clinical claim on this site is sourced to a named, published peer-reviewed trial. Weight-loss percentages are accompanied by the specific study they come from. We distinguish between NewSelf's marketing claims and independent clinical evidence. We cite the FDA warning letter. We publish the AllyRx 2.7/5 user score alongside the Trustpilot 4.5 — not just the more flattering number. We disclose the 3-month commitment terms and cancellation fees prominently because they affect financial decisions. Read our full editorial policy.

What This Site Covers

Our content covers the NewSelf GLP-1 program across every dimension a prospective patient needs: Semaglutide Plus⁺ and Tirzepatide Plus⁺ medication details, complete pricing analysis, step-by-step process guide, clinical eligibility, compounding safety, 5,000-word independent review, competitor comparisons, FDA regulatory coverage, and a 15-post blog covering every angle of the NewSelf decision. See our clinical sources for the trial citations underlying all efficacy claims.

Contact

For editorial corrections, factual updates, or questions about our affiliate relationships: contact page. For NewSelf customer service, billing, or medical support, contact NewSelf directly at 1-855-606-5232 or support@newself.com — we cannot assist with NewSelf account issues.